Congress at a Glance
Scientific Programme
Satellite Programme
Maps of the Venue
Search in:
 Papers, Programme or All
 Please use only plain characters
 (e.g., e, o, c and not è, ö or ç)
 		 
   
  Author   or    Free text  
   
  Author list  

  Personal Planner:
  Create a new login and password click here
Nb. Only your Personal Planner login is valid!
  Username Password  
   
 
  


Track:
  Treatment track
  Clinical research track
  Interface track
  Preclinical track
  Educational updates track

 
Scientific Programme Track:
View last minute changes Last minute changes
Back to overview
12:00-14:00 , Monday, 01 September 2008
Poster session page: 1 2   

12:00-14:00
P.2.a:  Affective disorders and antidepressants - Affective disorders (clinical)
Poster area

P.2.a.001  Efficacy of agomelatine from treatment initiation to treatment completion  Paper: P.2.a.001
S.H. Kennedy*, Canada
 

P.2.a.002  Treatment milestones predict symptom remission over 6-month treatment of patients with major depressive disorder (MDD)  Paper: P.2.a.002
A. Wade*, T.E. Schlaepfer, C.D. Kilts, United Kingdom
 

P.2.a.003  Baseline severity of depression predicts antidepressant drug response  Paper: P.2.a.003
A.G. Wade*, C.D. Kilts, T.E. Schlaepfer, Germany
 

P.2.a.004  Use of antidepressants in older people with mental illness  Paper: P.2.a.004
S. Curran*, A. Byrne, J.P. Wattis, United Kingdom
 

P.2.a.005  Duloxetine for premenstrual dysphoric disorder  Paper: P.2.a.005
M. Mazza*, D. Harnic, V. Catalano, L. Janiri, P. Bria, Italy
 

P.2.a.006  A comparison of quality of life, anxiety and depression in patients with macular degeneration and cataract patients  Paper: P.2.a.006
M. Hyper-Ochalik*, K. Krysta, I. Krupka-Matuszczyk, M. Sygut, Poland
 

P.2.a.007  Variations in tryptophan hydroxylase 2 are associated with elevated risk for metabolic syndrome in depression  Paper: P.2.a.007
S. Kloiber*, M.A. Kohli, T. Brueckl, M. Ising, M. Uhr, A. Menke, B. Muller-Myhsok, F. Holsboer, S. Lucae, Germany
 

P.2.a.008  Comparative study on the effectiveness of anti-depressing treatment between st. John’s wort and duloxetine  Paper: P.2.a.008
C. Istikoglou*, D. Vlissides, V. Mavreas, Greece
 

P.2.a.009  Pooled analysis: 2 randomised clinical trials confirms superiority of escitalopram over paroxetine in treatment of major depressive disorder  Paper: P.2.a.009
S. Kasper*, D. Baldwin, J.P. Boulenger, France
 

P.2.a.010  The depression inventory development workgroup: results from the second validation study  Paper: P.2.a.010
A. Kalali*, A. Vaccarino, K. Evans, S. Kennedy, K. Kobak, T. Sills, D. Sheehan, J. Williams, J. Greist, A. Schatzberg, USA
 

P.2.a.011  Efficacy of duloxetine in painful symptoms with major depressive disorder  Paper: P.2.a.011
J. Castaño*, C. Garnier, D. Córcoles, L. Rodriguez, B. Diaz, L.M. Martin, A. Bulbena, Spain
 

P.2.a.012  A diagnosis of depression is associated with increased hypnotic use in primary care  Paper: P.2.a.012
J. Donoghue*, M. Lader, D. Stahl, United Kingdom
 

P.2.a.013  Outcome situations of patients, after admission at the emergency room, with suicidal attempt  Paper: P.2.a.013
P. Minner*, D. Lorge, H. Cornet, D. Neu, I. Pelc, P. Verbanck, Belgium
 

P.2.a.014  The clinical characteristics of major depressive disorder with psychotic features  Paper: P.2.a.014
M.H. Kang*, S.W. Han, C.E. Kim, J.S. Lee, J.N. Bae, S.Y. Lee, South-Korea
 

View last minute changes
P.2.a.015  Weight gain and antidepressants: a comprehensive review and meta analysis  Paper: P.2.a.015
L. Mandelli*, J.L. Díaz-Galvis, D. De Ronchi, A. Serretti, Italy
L. Mandelli* will be replaced by A. Serretti
 

P.2.a.016  BDNF in plasma following electroconvulsive therapy: a pilot study in depressed patients  Paper: P.2.a.016
A. Del Debbio*, C. Bianchi, I. Roncaglia, A. Mariotti, M.C. Dell'Osso, C. Mannari, N. Origlia, S. Zanello, D. Marazziti, A. Piccinni, Italy
 

P.2.a.017  Comparison of the psychometric properties of the self-rating scales hospital anxiety and depression scale (HADS) and patient health questionnaire (PHQ-9)  Paper: P.2.a.017
M. Hansson*, O. Bodlund, G. Nyberg, Sweden
 

P.2.a.018  Comparison of depressive symptoms of major depressive disorder between elderly and non-elderly group in South Korea  Paper: P.2.a.018
Y.M. Jae*, J.G. Kim, D.S. Lee, South-Korea
 

P.2.a.019  Depression, anxiety and quality of life following acute myocardial infarction in a sample of Turkish population  Paper: P.2.a.019
S. Ozdemir*, N. Kocabasoglu, Z. Ongel, I. Yalug, Turkey
 

P.2.a.020  Gender differences in patterns of neurocognitive impairment during the acute phase of major depression  Paper: P.2.a.020
A. Sarosi*, X. Gonda, G. Balogh, G. Faludi, Hungary
 

P.2.a.021  Heart rate variability and depressive symptoms in general population  Paper: P.2.a.021
Y. Park*, S.H. Kim, J.W. Ahn, South-Korea
 

P.2.a.022  Psychiatric morbidity in infertility among a sample of egyptian women: the impact on treatment outcome  Paper: P.2.a.022
D. Radwan*, Ramy H. , A. Khalil, M. Mansour, M. El-Sayed, K.H. Moussa, A. El-Missiry, Egypt
 

P.2.a.023  Effect of polymorphisms in the tryptophan hydroxylase 2 gene on suicide risk in Korean with major depressive disorder  Paper: P.2.a.023
Y.Y. Nam*, C.H. Kim, D.Y. Cho, H.S. Lee, South-Korea
 

View last minute changes
P.2.a.024  Vagus nerve stimulation for treatment-resistant depression: open-label European study - 24-month outcomes  Paper: P.2.a.024
J. Allen*, USA
Withdrawn
 

P.2.a.025  The differences in abnormal illness behavior questionnaire between non-somatization and somatization group  Paper: P.2.a.025
Y.M. Jae*, S.H. Jang, D.S. Lee, South-Korea
 

P.2.a.026  Effects of metoclopramide on 5-HTP induced activation of the hypothalamus-pituitary-adrenal (HPA) axis  Paper: P.2.a.026
G. Jacobs*, E.G.J. Hulskotte, M. de Kam, F.G. Zitman, J.M.A. van Gerven, The Netherlands
 

P.2.a.027  Association between tryptophan hydroxylase 2 gene and the personality traits of novelty seeking and harm avoidance  Paper: P.2.a.027
Y.Y. Nam*, H.S. Lee, D.Y. Cho, C.H. Kim, South-Korea
 

P.2.a.028  Relapse prevention and residual symptoms; further analyses of clinical studies with escitalopram in MDD, GAD, SAD, OCD  Paper: P.2.a.028
P. Bech*, K.F. Overø, Denmark
 

P.2.a.029  A possible case of venlafaxine-associated parapsoriasis  Paper: P.2.a.029
A. Erol*, M. Ermete, O. Aydin, Turkey
 

P.2.a.030  Intravenous augmentation in resistant major depressive episode: preliminary results in a naturalistic study  Paper: P.2.a.030
M.F. Bosi*, R. Bassetti, A. Colombo, G. Valentini, G. Luce, C.A. Vigano, G. Ba, Italy
 

P.2.a.031  Serotonin syndrome resulting from coadministration of venlafaxine, and mirtazapine  Paper: P.2.a.031
N. Atasoy*, D. Ozturk, N. Konuk, Turkey
 

P.2.a.032  Prevalence and correlates of unexplained pain in depressed psychiatric outpatients. The dedo-psychiatry study  Paper: P.2.a.032
L. Agüera-Ortiz*, J.A. Micó, I. Failde, J. Cervilla, Spain
 

P.2.a.033  Venlafaxine versus selective serotonin reuptake inhibitors in mixed major depression and dysthymic disorder  Paper: P.2.a.033
D. Vasiliu*, O. Vasiliu, C. Tudor, D. Patriche, B. Stanescu, D. Ojog, Romania
 

P.2.a.034  Plasma dehydroepiandrosterone sulphate (DHEAS) and cortisol in patients with mood disorders  Paper: P.2.a.034
G. Camardese*, B. Mattioli, G. Pizi, L. Pucci, P. Bria, Italy
 

P.2.a.035  Inflammatory response and psychopathological dimensions in major depression  Paper: P.2.a.035
G. Camardese*, G. Pizi, B. Mattioli, R.L. Grillo, L. Pucci, P. Bria, Italy
 

P.2.a.036  Analyses of haplotypes tagging the serotonin transporter gene (SLC6A4) provide new evidence for the gene x environment model of depression  Paper: P.2.a.036
J. Lazary*, A. Lazary, X. Gonda, A. Benko, E. Molnar, D. Papp, G. Juhász, G. Bagdy, Hungary
 

P.2.a.301  Gender difference in risk factors for major depression
A. Chirita*, C. Streba, Romania
 

P.2.a.302  Sexuality of people with depression
R. Kowalczyk*, A. Janas, A. Steposz, A. Skrzypulec, I. Krupka-Matuszczyk, Poland
 

P.2.a.303  Correlation between anxiety and cognitive functions
J. Przybylo*, K. Krysta, I. Krupka-Matuszczyk, Poland
 

12:00-14:00
P.2.b:  Affective disorders and antidepressants - Affective disorders (basic)
Poster area

P.2.b.001  Contribution of some serotonergic system genes to suicidal behaviour in Russian population: gender specific association  Paper: P.2.b.001
Z. Khalilova*, D. Gaysina, A. Kazantseva, E. Khusnutdinova, Russia
 

P.2.b.002  Association between two gene polymorphisms (SNPs) of tryptophan hydroxylase gene and suicidal behavior in depressive patients  Paper: P.2.b.002
H.K. Yoon*, Y.K. Kim, B.H. Lee, South-Korea
 

P.2.b.003  The effects of antidepressants on the progress of weight gain and in diabetic (OLETF) and non-diabetic (LETO) rats  Paper: P.2.b.003
B. Kee*, W. Hahm, K. Joe, S. Kim, South-Korea
 

P.2.b.004  The chronic variable stress sensitizes the startle reflex to footshock  Paper: P.2.b.004
S. Kanai*, K. Fujiwara, T. Yanagida, M. Nakano, D. Tanaka, M. Asakura, Japan
 

P.2.b.005  Anhedonic depression: an endophenotypic approach  Paper: P.2.b.005
E. Vrieze*, D. Pizzagalli, S. Claes, USA
 

P.2.b.006  Effects of agomelatine and fluoxetine on hippocampal cell survival, glucocorticoid receptors and BDNF expression in a model of depression  Paper: P.2.b.006
E. Païzanis*, V. Lelièvre, F. Saurini, N. Barden, C. Gabriel, E. Mocaër, M. Hamon, L. Lanfumey, France
 

P.2.b.007  The effect of sub-convulsive electrical stimulation and electroconvulsive therapy (ECT) in a rat model for depression  Paper: P.2.b.007
E. Toth*, R. Gersner, A. Zangen, Israel
 

P.2.b.008  The effects of antidepressants on the expression of UCP-1,2,3 mRNA in the animal model of metabolic syndrome  Paper: P.2.b.008
H.T. Jeon*, K.H. Joe, H.T. Kim, D.J. Kim, South-Korea
 

P.2.b.009  The effect of fluvoxamine on akt-1 phosphorylation and total akt-1 protein levels by immunoblotting in PC12 neuronal cells  Paper: P.2.b.009
M. Nakano*, A. Misono, K. Fujiwara, T. Yanagida, S. Kanai, D. Tanaka, K. Osada, M. Asakura, Japan
 

P.2.b.010  PKC blockade prevents the in vivo allosteric modulation of the 5-HT transporter induced by escitalopram.  Paper: P.2.b.010
N. Haddjeri*, L. Lambas-Senas, M. El Mansari, L. Zimmer, C. Sánchez, O. Mnie-Filali, Denmark
 

P.2.b.011  Relationship of variations in the leptin receptor (LEPR) gene and depressive symptoms is moderated by severe trauma  Paper: P.2.b.011
P. Zimmermann*, S. Kloiber, T. Brueckl, H. Pfister, H.U. Wittchen, F. Holsboer, M. Ising, R. Lieb, Germany
 

P.2.b.012  Depressive coping style predicts the relationship between cortisol responses and stress experience  Paper: P.2.b.012
P. Netter*, R. Hueppe, K. Pohl, Germany
 

P.2.b.013  The antidepressant effect of the hypericum extracts Ze-117 and LI-160 depends on total liver's cytochrome P450 activity  Paper: P.2.b.013
I. Bellido*, M.R. Cabello, E. Blanco, E. Marquez, A. Gomez-Luque, Spain
 

P.2.b.014  Chronic stress in rats as model for depression: effects of citalopram on expression of TPH isoforms 1 and 2  Paper: P.2.b.014
N. Abumaria*, A. Ribic, C. Anacker, G. Flugge, Germany
 

P.2.b.015  Lu AA21004: a novel potential treatment for mood disorders  Paper: P.2.b.015
N. Moore*, B. Bang-Andersen, L. Brennum, K. Fredriksen, S. Hogg, A. Mork, T. Stensbol, H. Zhong, C. Sanchez, D. Smith, USA
 

P.2.b.016  Effects of antidepressant treatment on the intensity dependence of auditory evoked potential components  Paper: P.2.b.016
T. Linka*, J. Wiltfang, G. Sartory, B.W. Mueller, The Netherlands
 

P.2.b.017  Lack of CB1 receptor alters serotonin system: an electrophysiological and in vivo microdialysis study  Paper: P.2.b.017
E. Aso*, T. Renoir, C. Ledent, M. Hamon, R. Maldonado, L. Lanfumey, O. Valverde, Spain
 

P.2.b.018  Hippocampal cytogenesis is increased in a genetic rat model of depression. Escitalopram reduces increased cell number  Paper: P.2.b.018
A. Mathé*, S.H.M. Gruber, G. Wörtwein, A. Petersén, Sweden
 

P.2.b.019  Family burden of patients with unipolar and bipolar affective disorders  Paper: P.2.b.019
J. Borowiecka-Kluza*, D. Dudek, M. Siwek, Poland
 

P.2.b.020  Roles of GABA in regulating sensitivity of tyrosine hydroxylase activity in locus coeruleus to chronic variable stress  Paper: P.2.b.020
D. Tanaka*, S. Kanai, T. Yanagida, K. Fujiwara, M. Nakano, K. Osada, M. Asakura, Japan
 

P.2.b.021  Gender differences in serotonin transporter availability in patients with major depression  Paper: P.2.b.021
K. Uebelhack*, L. Franke, N. Herold, M. Plotkin, H. Amthauer, R. Uebelhack, Germany
 

12:00-14:00
P.2.c:  Affective disorders and antidepressants - Antidepressants (clinical)
Poster area

P.2.c.001  Antidepressant treatment in a primary mental health center- tolerability and clinical improvement- patients opinion  Paper: P.2.c.001
A. Falces*, C. Conesa, R. Borrego, T. Bel, A. Corominas, Spain
 

P.2.c.002  A heterogeneity of depression: views from dynamics of blood levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF)  Paper: P.2.c.002
R. Yoshimura*, J. Nakamura, N. Ueda, A. Ikenouchi-Sugita, W. Umene-Nakano, Japan
 

P.2.c.003  Imipramine, venlafaxine or venlafaxine plus quetiapine in psychotic depression, a randomized, double-blind study  Paper: P.2.c.003
W. Nolen*, J. Wijkstra, H. Burger, W.W. Van den Broek, R.J. Verkes, T.K. Birkenhager, J.G.E. Janzing, M.L.M. Van der Loos, M.L.T. Breteler, G.M.G.I. Ramaekers, The Netherlands
 

P.2.c.004  Antidepressants are associated with increased length of hypnotic use in primary care  Paper: P.2.c.004
J. Donoghue*, M. Lader, United Kingdom
 

P.2.c.005  Meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder  Paper: P.2.c.005
M. Kato*, A. Serretti, Italy
 

P.2.c.006  Trazodone in the treatment of fibromyalgia: a 12 weeks open label study.  Paper: P.2.c.006
R. Molina-Barea*, E.P. Calandre, P. Morillas-Arques, C.M. Rodriguez-Lopez, J.M. Garcia-Leiva, J.S. Vilchez, F. Rico-Villademoros, Spain
 

P.2.c.007  Algorithm for the management of treatment-resistant depressions based on the antidepressant combinations  Paper: P.2.c.007
J. De la Gándara*, L. Agüera, E. Rojo, S. Ros, Spain
 

P.2.c.008  Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation  Paper: P.2.c.008
A. Zourkova*, J. Jurica, E. McCaskey Hadasova, L. Pulkrabkova, Czech Republic
 

P.2.c.009  Preliminary analysis of trazodone and pregabalin association in the treatment of fibromyalgia.  Paper: P.2.c.009
J. Vilchez*, P. Morillas-Arques, C.M. Rodriguez-Lopez, R. Molina-Barea, J.M. Garcia-Leiva, E.P. Calandre, F. Rico-Villademoros, Spain
 

P.2.c.010  The effect of treatment on BMI, attitudes and psychopathology in eating disorders  Paper: P.2.c.010
E. Ceskova*, T. Kasparek, J. Dufek, D. Valentova, I. Palcikova, R. Dockalova, Czech Republic
 

P.2.c.011  An open study of quietiapine augmentation in treatment resistant depression  Paper: P.2.c.011
I. Anderson*, A. Sarsfield, P. Haddad, United Kingdom
 

P.2.c.012  Serotonin transporter promoter polymorphism does not influence treatment response to escitalopram in depression  Paper: P.2.c.012
E. Maron*, A. Tammiste, K. Kallassalu, T. Eller, V. Vasar, D. Nutt, A. Metspalu, Estonia
 

P.2.c.013  Comparative efficacy of the antidepressants agomelatine, venlafaxine and sertraline  Paper: P.2.c.013
S. Kasper*, P. Lemoine, Austria
 

P.2.c.014  Tandospirone augmentation therapy is useful in depressed patients with inadequate response to SSRIs or SNRIs  Paper: P.2.c.014
A. Sumiyoshi*, K. Miki, M. Kamimura, K. Yamada, Japan
 

P.2.c.015  The effect of paroxetine on amygdala reactivity after emotional faces measured with fMRI  Paper: P.2.c.015
H.G. Ruhe*, J. Booij, D.J. Veltman, J.B. Reitsma, M.C. Michel, A.H. Schene, The Netherlands
 

P.2.c.016  A survey of patients being prescribed SSRI’s by their general practitioner in the UK  Paper: P.2.c.016
A. Wade*, G.M. Crawford, V. Bezlyak, United Kingdom
 

View last minute changes
P.2.c.017  Do tramadol and dopamine-blocking agents enhance the risk of mirtazapine-associated restless legs syndrome?  Paper: P.2.c.017
S.W. Kim*, J.H. Lee, K.H. Chung, J.M. Kim, I.S. Shin, J.S. Yoon, S.J. Yang, South-Korea
S.W. Kim* will be replaced by J.H. Lee
 

P.2.c.018  ACTH and cortisol in major depressive disorders: antidepressant responders and non-responders  Paper: P.2.c.018
Y. Jeon*, E. Park, J. Yi, South-Korea
 

P.2.c.019  Early prediction of clinical response in patients with major depressive disorder receiving fluoxetine  Paper: P.2.c.019
C.H. Lin*, K.S. Lin, M.C. Chen, L.S. Chou, C.C. Chen, Taiwan
 

P.2.c.020  Prospective study of pharmacogenetic polymorphisms and response to antidepressants over 8 weeks in major depression  Paper: P.2.c.020
C.H. Ng*, I. Schweitzer, K. Byron, A. Singh, L.H. Peh, W.K. Tay, C.H. Tan, M. Berk, Australia
 

P.2.c.021  Use of antidepressants in psychiatric emergency departments. A prospective study from 2003 to 2006  Paper: P.2.c.021
C. Garnier*, J. Castaño, D. Córcoles, N. Espluga, J.M. Ginés, B. Díaz, L.M. Martín, A. Merino, A. Bulbena, Spain
 

P.2.c.022  Superior antidepressant efficacy of agomelatine versus sertraline: a randomised, double-blind study  Paper: P.2.c.022
S. Kasper*, L. Laigle, F. Baylé, Austria
 

P.2.c.023  Are moclobemide trough concentrations an adequate predictor of the systemic drug exposure  Paper: P.2.c.023
A. Rakic Ignjatovic*, B. Miljkovic, D. Todorovic, I. Timotijevic, M. Pokrajac, Serbia
 

P.2.c.024  Perception of antidepressants in primary care: profile of patients prescribed newer antidepressants in the United Kingdom  Paper: P.2.c.024
D. Saragoussi*, D. Milea, N. Despiégel, F. Guelfucci, France
 

P.2.c.025  Long-term treatment with agomelatine: prevention of relapse in patients with Major Depressive Disorder over 10 months  Paper: P.2.c.025
G.M. Goodwin*, F. Rouillon, R. Emsley, United Kingdom
 

P.2.c.026  A new strategy of continuation pharmacotherapy in the prevention of relapse following ECT: a controlled trial  Paper: P.2.c.026
A. Yildiz*, A. Mantar, S. Simsek, E. Onur, Turkey
 

P.2.c.027  Healthcare cost associated with first-line antidepressant treatments in severe depression in the United Kingdom  Paper: P.2.c.027
A.G. Wade, D. Saragoussi*, N. Despiégel, F. Guelfucci, C. François, France
 

View last minute changes
P.2.c.028  Antidepressant-associated sexual dysfunction: naturalistic setting  Paper: P.2.c.028
C.T. Lee*, H.K. Lee, Y.S. Kweon, K.U. Lee, South-Korea
Withdrawn
 

View last minute changes
P.2.c.029  Improving clinical signal detection for novel antidepressants using Bayesian bootstrap monitoring and placebo estimates  Paper: P.2.c.029
E. Merlo Pich*, R. Gomeni, Italy
Withdrawn
 

P.2.c.030  Sexual dysfunction in a group of depressed female patients  Paper: P.2.c.030
C. Mihailescu*, A. Mihailescu, Romania
 

P.2.c.031  A national patient sleep assessment questionnaire in depression (NAPSAQ II); a survey for general practitioners  Paper: P.2.c.031
L.M. Paterson*, D.J. Nutt, S.J. Wilson, United Kingdom
 

View last minute changes
P.2.c.032  A full antagonist of 5-HT1a receptors does not reduce the latency of SSRIs effect
Portella, M.J.(1)*; Puigdemont, D.(1); Perez-Egea, R.(1); Alvarez, E.(1); Artigas, F.(2); Spain
Withdrawn
 

P.2.c.033  The efficacy of desvenlafaxine for improving functioning and quality of life measures in patients with major depressive disorder  Paper: P.2.c.033
C. Soares*, M. Thase, S. Kornstein, C. Brisard, L. Septien-Velez, J.M. Germain, B. Pitrosky, A. Patroneva, Q. Jiang, P. Ninan, R. Ganguly, USA
 

P.2.c.034  Persistent hiccups successfully treated with mirtazapine  Paper: P.2.c.034
S. Chung*, Y.M. Oh, J.C. Yang, J.Y. Lee, T.S. Ha, T.W. Park, Y.C. Chung, I.K. Hwang, South-Korea
 

P.2.c.035  Health care utilization and costs of depressed patients treated with escitalopram versus SNRIs  Paper: P.2.c.035
M.H. Erder*, E. Wu, R. Ben-Hamadi, N. Beaulieu, M. Lu, USA
 

P.2.c.036  Treatment compliance and health care costs of medicaid depressed adult patients treated with escitalopram versus citalopram  Paper: P.2.c.036
M.H. Erder*, E. Wu, M. Lu, R. Ben-Hamadi, N. Beaulieu, USA
 

P.2.c.037  Prevalence and correlates of depression in patients with unexplained pain in primary care. The dedo-primary care study  Paper: P.2.c.037
L. Agüera-Ortiz*, J.A. Micó, I. Failde, J. Cervilla, Spain
 

P.2.c.301  Enuresis induced by serotonin-selective reuptake inhibitor (SSRI): case report
M. Dr. Darghal*, C. Dr. Essaidi, Morocco
 

12:00-14:00
P.2.d:  Affective disorders and antidepressants - Antidepressants (basic)
Poster area

P.2.d.001  Beta-arrestin plays a major role in the mechanism of action of antidepressant drugs  Paper: P.2.d.001
M. Golan*, G. Schreiber, S. Avissar, Israel
 

P.2.d.002  Effects of chronic social stress and fluoxetine treatment on the vascular niche and neurogenesis in the hippocampus  Paper: P.2.d.002
B. Czéh*, E. Fuchs, Germany
 

P.2.d.003  Excitatory effect of the atypical antidepressant tianeptine in the rat hippocampus: in vitro study  Paper: P.2.d.003
G. Kapus*, M. Vegh, I. Gacsályi, M. Spedding, L.G. Harsing Jr., Hungary
 

P.2.d.004  Modulation of locus coeruleus noradrenergic neurons by fluoxetine  Paper: P.2.d.004
C. Miguelez*, M. Torrecilla, I. Fernandez, L. Grandoso, L. Ugedo, Spain
 

P.2.d.005  Stress-induced changes of neuroplastic proteins and modulation by chronic antidepressant treatment  Paper: P.2.d.005
F. Calabrese*, R. Molteni, G. Racagni, M.A. Riva, Italy
 

P.2.d.006  Effects of agomelatine and S32006, a selective 5-HT2C receptor antagonist, in chronically-stressed tree shrews  Paper: P.2.d.006
E. Fuchs*, S. Corbach-Söhle, B. Schmelting, E. Mocaer, M.J. Millan, C. Gabriel-Gracia, Germany
 

P.2.d.007  The effects of antidepressants on the weight, blood glucose, leptin, and adiponectin in diabetic (OLETF) and non diabetic (LETO) rats.  Paper: P.2.d.007
H.T. Jeon*, G.H. Joe, B.S. Kee, South-Korea
 

P.2.d.008  Agomelatine counteracts alteration in circadian rhythms observed in old hamsters  Paper: P.2.d.008
E. Mocaer*, O. Van Reeth, J. Mairesse, A. Giovine, G. Mennuni, A. Catalani, S. Maccari, France
 

P.2.d.009  Cellular and molecular mechanisms underlying increased adult hippocampal neurogenesis induced by agomelatine  Paper: P.2.d.009
A. Soumier*, S. Lortet, C. Gabriel, E. Mocaer, M.J. Millan, A. Daszuta, France
 

P.2.d.010  Relation between weight and plasma leptin levels in female during antidepressant treatment.  Paper: P.2.d.010
L. Bossini*, E. Pierantozzi, L. Padula, M. Di Rienzo, A. Fagiolini, P. Castrogiovanni, Italy
 

P.2.d.011  Genes expression and protein levels in rat brain, dependent on time passage after administration of antidepressant dugs  Paper: P.2.d.011
M. Kusmider*, A. Faron-Górecka, J. Solich, P. Palach, M. Dziedzicka-Wasylewska, Poland
 

P.2.d.012  Further characterization of norquetiapine and quetiapine in rodent models of antidepressant and anxiolytic action  Paper: P.2.d.012
T. Hudzik*, J. Zhou, B. Brockel, E. Sutton, C. Maciag, S. Grimm, Z. Zeller, D. Widzowski, USA
 

P.2.d.013  F15599, a post-synaptic cortical preferential 5-HT1A agonist: I) functionally-selective signal transduction profile  Paper: P.2.d.013
A. Newman-Tancredi*, J.C. Martel, J. Buritova, E. Lauressergues, M.B. Assie, L. Bruins Slot, C. Cosi, P. Heusler, D. Cussac, France
 

P.2.d.014  F15599, a post-synaptic cortical preferential 5-HT1A agonist: II) Effect in rodent models of cognition / memory deficits  Paper: P.2.d.014
R. Depoortere*, A. Auclair, L. Bardin, A. Newman-Tancredi, France
 

P.2.d.015  Effects of antidepressants on behavioural despair in olfactory bulbectomized rats  Paper: P.2.d.015
V. Roman*, R. Kedves, I. Gyertyan, Hungary
 

P.2.d.016  Depressive-resistant behavioural phenotype in mice overexpressing cannabinoid CB2 receptors  Paper: P.2.d.016
M.S. García-Gutiérrez*, J. Manzanares, Spain
 

P.2.d.017  Ketanzerine modulates expression of 5-HT2A/2C- and 17b-estradiol receptors mRNAs in female rats in forced swim test  Paper: P.2.d.017
J. Fedotova*, N. Losev, Russia
 

P.2.d.018  Proteome changes in rat hippocampus and pre-frontal/frontal cortex in Flinders rats after escitalopram treatment  Paper: P.2.d.018
C. Piubelli*, S. Becchi, A. El Khoury, W. Andersson, S. Gruber, A.A. Mathé, E. Domenici, L. Carboni, Italy
 

P.2.d.019  Proteome changes in rat hippocampus and pre-frontal/frontal cortex in Flinders rats after nortriptyline treatment  Paper: P.2.d.019
L. Carboni*, C. Piubelli, M. De Luca, S. Gruber, W. Andersson, A. El Khoury, A.A. Mathé, E. Domenici, Italy
 

P.2.d.020  Saredutant (SR48968), a NK2 receptor antagonist, blocks chronic stress-induced decrease in neurogenesis in Balb/c mice  Paper: P.2.d.020
J. Stemmelin*, B. Canolle, V. Roudières, C. Labie, J. Fournier, C. Cohen, G. Griebel, France
 

P.2.d.021  Individual differences in the effect of a CRF1 receptor antagonist on anxiety-related behavior and corticosterone levels  Paper: P.2.d.021
J. Harro*, T. Mällo, Estonia
 

P.2.d.022  Do antidepressant drugs affect aversive memory functions in the forced swim test?  Paper: P.2.d.022
T. Wardi*, E. Toth, S.O. Ogren, Sweden
 

P.2.d.023  In vitro pharmacological profile of doxepin, a sleep-promoting histamine H1 antagonist  Paper: P.2.d.023
R. Mansbach*, USA
 

P.2.d.024  Hippocampal neuroplasticity is involved in the antidepressant-like effects of 5-HT4 receptor partial agonist SL 65.0155  Paper: P.2.d.024
A. Tamburella*, V. Micale, A. Navarria, F. Drago, Italy
 

P.2.d.025  SSRI-induced inhibition of dopamine neuronal activity is reversed by antagonism of serotonin-2C receptors  Paper: P.2.d.025
E. Dremencov*, M. El Mansari, P. Blier, Canada
 

12:00-14:00
P.2.e:  Affective disorders and antidepressants - Bipolar disorders (clinical)
Poster area

P.2.e.001  Social adjustment during childhood and adolescence: bipolar patients outperform healthy controls  Paper: P.2.e.001
T.G. Schulze*, A. Georgi, C. Schmael, F. Schirmbeck, J. Strohmaier, K.V. Boesshenz, M.M. Nöthen, M. Rietschel, Germany
 

P.2.e.002  Psychoeducational intervention in families of patients with bipolar disorder  Paper: P.2.e.002
A. González-Pinto*, P. Vega, F. Mosquera, P. Lopez, M. Gutierrez, Spain
 

P.2.e.003  Duration of untreated illness (DUI) in bipolar disorder: a naturalistic study  Paper: P.2.e.003
B. Dell'Osso*, M. Buoli, G. Camuri, V. Vecchi, A.C. Altamura, Italy
 

P.2.e.004  The Hamilton depression scale may not be an adequate tool for an assessment of mixed state symptoms  Paper: P.2.e.004
W. Drozdz*, A. Borkowska, W. Halota, Poland
 

P.2.e.005  Anticonvulsant treatment, B12 plasma levels and mood disorders  Paper: P.2.e.005
E. Neroutsos*, G. Vagionis, M. Fiste, Greece
 

P.2.e.006  Occupational outcome of lithium-treated bipolar patients in clinical remission  Paper: P.2.e.006
M.J. Portella*, M. Mur, A. Martinez-Aran, E. Vieta, Spain
 

P.2.e.007  Subjective experiences of bipolar patients in the residual or remitted phase  Paper: P.2.e.007
H. Yoon*, W. Cho, South-Korea
 

P.2.e.008  Low serum dehydroepiandrosteronesulphate is associated with interpersonal aggression in males with Bipolar 1 disorder  Paper: P.2.e.008
A.G.M. Johansson*, M. Landén, Sweden
 

P.2.e.009  Affective disorders - bipolarity – impulsivity. Results of a study with the Hungarian version of mood disorder questionnaire (MDQ)  Paper: P.2.e.009
P. Osvath*, Z. Omboli, V. Voros, S. Fekete, Hungary
 

P.2.e.010  Combined antidepressant and quetiapine therapy in bipolar I mixed – an open label study  Paper: P.2.e.010
G. Callista*, E. Daneluzzo, Italy
 

P.2.e.011  The role of psychotic features in bipolar disorder  Paper: P.2.e.011
I. Ozyildirim*, O. Yazici, S. Cakir, Turkey
 

P.2.e.012  Gender differencies in the treatment of severe bipolar affective and schyzoaffective disorders  Paper: P.2.e.012
J. Cobo*, R. Coronas, J.D. Barbero, N. Benito, M. Pérez, E. Pujals, G. Fuste, G. García-Parés, Spain
 

P.2.e.013  Searching susceptibility loci for bipolar disorder: a sib pairs study on chromosome 12  Paper: P.2.e.013
A. Pirovano*, E. Marino, D. Del Monte, F. Bongiorno, C. Lorenzi, E. Smeraldi, Italy
 

P.2.e.014  Are antiepileptic mood stabilizers really effective in psychotic bipolar mania?  Paper: P.2.e.014
D. Marinkovic*, S. Totic, M. Marjanovic, Serbia
 

P.2.e.015  Antiepileptic mood stabilizers (carbamazepine and valproate) in acute-phase psychotic bipolar mania treatment  Paper: P.2.e.015
S. Totic*, D. Marinkovic, M. Marjanovic, Serbia
 

P.2.e.016  Association of Tumor Necrosis Factor -308 G/A promoter polymorphism with schizophrenia and bipolar affective disorder  Paper: P.2.e.016
P. Kapelski*, P.M. Czerski, F. Rybakowski, J.K. Rybakowski, M. Dmitrzak- Weglarz, A. Leszczynska- Rodziewicz, A. Slopien, M. Skibinska, M. Kaczmarkiewicz- Fass, J. Hauser, Poland
 

P.2.e.017  Anticipation in bipolar disorders: a Comparison between the two generations  Paper: P.2.e.017
Z. Yuncu*, S. Kesebir, F. Akdeniz, S. Vahip, Turkey
 

P.2.e.018  Randomized, placebo, active-controlled study of paliperidone extended-release (ER) for acute manic and mixed episodes in bipolar I disorder  Paper: P.2.e.018
E. Vieta*, J. Berwaerts, I. Nuamah, P. Lim, E. Yuen, J. Palumbo, D. Hough, Spain
 

P.2.e.019  Adult attention-deficit hyperactivity disorder in bipolar disorder  Paper: P.2.e.019
L. Tamam*, G. Karakus, N. Ozpoyraz, Turkey
 

P.2.e.020  Effects of valproate and atypical antipsychotics on bone mineral density in female patients with bipolar disorder  Paper: P.2.e.020
J. Yang*, S.H. Joe, M.S. Lee, Y.H. Ko, S.H. Kim, I.K. Jung, South-Korea
 

P.2.e.021  A systematic review of controlled clinical trials in bipolar disorder  Paper: P.2.e.021
P. Mohr*, T. Novak, J. Cermak, M. Rodriguez, Czech Republic
 

P.2.e.022  Placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I)  Paper: P.2.e.022
A. Young*, S. McElroy, W. Chang, B. Olausson, B. Paulsson, M. Brecher, Canada
 

P.2.e.023  Placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN II)  Paper: P.2.e.023
A. Young*, S. McElroy, W. Chang, B. Olaulsson, B. Paulsson, M. Brecher, Canada
 

P.2.e.024  Double-blind extension studies of asenapine in patients with bipolar mania  Paper: P.2.e.024
R. McIntyre*, M. Cohen, J. Zhao, J. Panagides, A. Szegedi, Canada
 

View last minute changes
P.2.e.025  Serum brain derived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy  Paper: P.2.e.025
A. Suwalska*, M. Sobieska, D. Lojko, J.K. Rybakowski, Poland
A. Suwalska* will be replaced by J.K. Rybakowksi
 

P.2.e.301  Modafinil use in a man with bipolar disorder, controlled obstructive sleep apnoea and excessive day time sleepiness
Thomas Mayze*, Australia
 

P.2.e.302  Multicenter observational research with bipolar patients in clinical psychiatry: the ROCK study
R. Teijeiro Permuy*, E. Van Gent, The Netherlands
 

P.2.e.303  Prescribing in bipolar affective disorder in women of childbearing age
A. Dutta*, C. Willis, K.S. Naidoo, United Kingdom
 

P.2.e.304  Lamotrigine in treating emotional irritability in persons with personality disorder
G. Nikolic*, Z.O. Zikic, S.T.G. Tosic-Golubovic, M.S. Manojlovic, Serbia
 

P.2.e.305  Comparative effects of olanzapine and quetiapine monotherapy on subjective estimate of sleep in acute mania
B. Yoon*, W. Bahk, D. Jon, K. Min, S. Lee, S. Park, South-Korea
 

P.2.e.306  Frequency of suicide attempts in bipolar disorder, clinical features and it’s relation with comorbid diagnosis
I. Ozyildirim*, S. Cakir, S. Sahin, O. Yazici, Turkey
 

P.2.e.307  Isolated acute mania as a rare effect of tacrolimus – treated with short-time application of risperidone
P. Tonn*, S.C. Reuter, N. Dahmen, Germany
 

P.2.e.308  Which treatment is suitable: mood stabilizer alone or combination with antipsychotics?
E. Soyucok, N. Aydin, H.A. Eski, E. Yazici, E. Ozan*, I. Kirpinar, Turkey
 

P.2.e.309  Bipolar depression versus unipolar depression: can temperament and character features predict bipolarity?
E. Soyucok, N. Aydin, E.Ozan*, H.A. Eski, E. Yazici, I. Kirpinar, Turkey
 

View last minute changes
P.2.e.310  Development of a shared care system for managing lithium therapy
M. Agius, H. Wear*, R. Zaman, United Kingdom
H. Wear* will be replaced by R. Zaman
 

P.2.e.311  Management of life-threatening lithium toxicity by hemodialysis in a patient with bipolar disorder
S. Chung*, H.M. Kim, T.S. Ha, J.C. Yang, T.W. Park, Y.C. Chung, I.K. Hwang, South-Korea
 

12:00-14:00
P.2.f:  Affective disorders and antidepressants - Bipolar disorders (basic)
Poster area

12:00-14:00
P.2.g:  Affective disorders and antidepressants - Other (clinical)
Poster area

P.2.g.001  Milnacipran and atomoxetine: treatment of depressive disorder with co-morbid hyperactivity disorder  Paper: P.2.g.001
I. Martsenkovsky*, I.I. Martsenkovska, Y.B. Bikshaeva, Ukraine
 

P.2.g.002  Stroke in psychiatric patients: relationship with cardiovascular risk factors and psychiatric medications  Paper: P.2.g.002
J.A. Díaz-Peromingo, M.T. Amboage-Paz, E. Fontela-Vivanco*, S. González-Bardanca, M.J. Ávila-González, Y. Prieto-Paredes, Spain
 

P.2.g.003  Type D personality and depression in Portuguese patients with acute coronary syndrome: identifying high risk groups  Paper: P.2.g.003
J. Prata*, S. Ramos, R. Coelho, Portugal
 

P.2.g.004  Changes of depressive symptoms after antidepressant treatment in the patients with chronic hemodialysis and depression  Paper: P.2.g.004
S. Park*, Y. Jung, E. Min, W. Cho, H. Rim, South-Korea
 

P.2.g.005  Occurrence of sexual dysfunction during the maintenance treatment with newer antidepressants (naturalistic study)  Paper: P.2.g.005
A. Zourkova*, J. Novotna, M. Vecerova, P. Havlikova, L. Pulkrabkova, Czech Republic
 

P.2.g.006  Practising according to treatment guidelines, are we doing it and is it important?  Paper: P.2.g.006
V. Agrawal*, S. Agrawal, United Kingdom
 

P.2.g.007  Association of antidepressants with episodes of schizophrenia  Paper: P.2.g.007
S. Purvina*, M. Caune, L. Kevere, Latvia
 

P.2.g.008  Extended release quetiapine fumarate monotherapy as maintenance treatment in patients with major depressive disorder (MDD)  Paper: P.2.g.008
C. Datto*, R.W. Lam, U. Lepola, D. Sweitzer, H. Eriksson, USA
 

P.2.g.009  Follow-up study of suicide attempters by jumping in five years  Paper: P.2.g.009
F. Vasquez*, Y. Nicolas, S. Falconi, V. Vite, Peru
 

P.2.g.010  Psychopharmacotherapy depressive disorders of patients suffering from malignant neoplasms  Paper: P.2.g.010
S. Tabachnikov, A. Vasylyeva*, S. Bugaytsov, Y.U. Martinenko, Ukraine
 

P.2.g.011  Significant effect of sertraline on dopamine transporter (DAT) in major depression measured by ß-CIT SPECT  Paper: P.2.g.011
Z. Szabó*, Z.S. Besenyi, M. Árgyelán, G. Eördegh, G.Y. Godó, A. Szkalicki, L. Pávics, Z. Janka, Hungary
 

View last minute changes
P.2.g.012  Estimation of therapeutic efficacy of magnetic fields in patients with drug-resistant depression  Paper: P.2.g.012
J. Sobis*, R. Hese, M. Jarzab, A. Sieron, P. Gorczyca, R. Pudlo, J. Matysiakiewicz, Poland
J. Sobis* will be replaced by R. Hese
 

P.2.g.013  Treating late life depression improves mild cognitive impairment  Paper: P.2.g.013
R.M. Chenderes*, C. Mila, D.M. Podea, P.D. Nanu, Romania
 

P.2.g.014  Practical issues of electroconvulsive therapy in Slovakia  Paper: P.2.g.014
J. Dragasek*, E. Palova, D. Breznoscakova, P. Mirossay, M. Drimalova, Slovak Republic
 

P.2.g.015  Improvement of mental health in psychiatric risk patients after treatment of chronic hepatitis C with interferon-alpha  Paper: P.2.g.015
M. Schäfer*, F. Schmidt, G. Janssen, G. Martin, M. Soyka, R. Lorenz, K. Loeschke, C. Folwaczny, Germany
 

P.2.g.016  Depression during low-dose interferon alpha treatment in patients with malignant melanoma  Paper: P.2.g.016
S. Heinze, S. Rötzer, M. Volkenandt, M. Schäfer*, Germany
 

P.2.g.301  Qualitative study of factors influencing patients’ decisions about antidepressant treatment
P. Schofield*, A. Tylee, L.Gask, A. Waquas, W. Waheed, A. Crosland, A. Wallace, A. Dickens, United Kingdom
 

12:00-14:00
P.2.h:  Affective disorders and antidepressants - Other (basic)
Poster area

P.2.h.001  Both R(-)- and S(+)- citalopram attenuates neuronal apoptosis in murine cortical cell culture  Paper: P.2.h.001
J.S. Noh*, Y.K. Chung, M.Y. Eu, South-Korea
 

P.2.h.002  The effect of different alpha-2 adrenoceptor ligands on aggression in mice  Paper: P.2.h.002
M. Votava*, L. Hess, M. Kriak, Czech Republic
 

P.2.h.003  The behavioral and cardiovascular effects of a novel partial alpha-2 adrenoceptor agonist naphthylmedetomidine  Paper: P.2.h.003
M. Votava*, L. Hess, J. Schreiberová, J. Málek, Czech Republic
 

P.2.h.004  The tryptophan hydroxylase a218c polymorphism in the korean patients with depressive disorder  Paper: P.2.h.004
H. Jeong*, S. Shim, Y. Kwon, Y. Hwang-bo, South-Korea
 

P.2.h.005  Serotonin levels and lymphocyte populations in female patients with depression: a comparative study  Paper: P.2.h.005
M. Figueiredo*, J.R. Garcia, F. Mota-Garcia, R. Mota-Cardoso, C.S. Cardoso, Portugal
 

12:00-14:00
P.4.a:  Anxiety disorders and anxiolytics - Anxiety disorders (clinical)
Poster area

P.4.a.001  Treatment of depressive and anxiety disorders with paroxetine in a sample of cancer survivors  Paper: P.4.a.001
S.Z. Baser*, N. Kocabasoglu, C. Papila, B. Papila, Turkey
 

P.4.a.002  Psychopharmacotherapy and suicidal behaviour of patients with anxiety and stress related disorders  Paper: P.4.a.002
N. Segrec*, M. Delic, P. Pregelj, Slovenia
 

P.4.a.003  The characteristics of salivary alpha-amylase reactivity to negative affective pictures  Paper: P.4.a.003
S.J. Lee*, H.D. Rim, S.R. Kim, J.H. Lee, S.M. Chang, E. Seo, U.S. Chung, S.H. Jeong, B.J. Kang, South-Korea
 

P.4.a.004  Remission in patients treated for generalized anxiety disorder in primary and psychiatric care: the MIRABEL study  Paper: P.4.a.004
M. Ansseau*, B. Sabbe, S. Vanbelle, A. Albert, A. Mignon, Belgium
 

P.4.a.005  An investigation of clinical factors influence the therapeutic response of paroxetine in patients with panic disorder  Paper: P.4.a.005
T. Ayugase*, S. Ishiguro, T. Watanabe, M. Ueda, Y. Saeki, G. Hirokane, S. Morita, N. Yamada, K. Akiyama, K. Shimoda, Japan
 

P.4.a.006  Evaluation of the prevalence of anxiety disorders with comorbidity of depression among geriatric psychiatry outpatients  Paper: P.4.a.006
F. Beskardes*, T. Ertan, Turkey
 

P.4.a.007  Contingent negative variation abnormalities in posttraumatic stress disorder.  Paper: P.4.a.007
P. Papart*, M. Ansseau, F. Bartholomé, Belgium
 

P.4.a.008  Comparison of anxiety-related traits between early and late onset panic disorder  Paper: P.4.a.008
Y.C. Shin*, S.W. Lim, S.W. Choi, I.K. Wang, K.S. Oh, South-Korea
 

P.4.a.009  Discrepancy betwe